Anti-aging glycopeptide (AAGP®)

See the science and potential of our patented AAGP® molecule

Floating molecules

“The molecule works, and it does what it says it’s going to do. This could be as big as the introduction of Tylenol or Penicillin.”

– Dr. Asim Raja, podiatrist and ProtoKinetix investor

Changing lives through cell survival

Become part of the next great medical discovery. AAGP®, our proprietary anti-aging glycopeptide has incredible opportunities to improve health therapies for ophthalmology, dermatology, transplants and biomanufacturing. By protecting cells against inflammation, AAGP® could be the essential link to medical advancements that provide more hope to more patients.

A woman and a child

AAGP® key benefits

AAGPs® are small, stable molecules that display abilities in resolving challenges confronting medical researchers in regenerative medicine. Because of its molecular makeup, AAGP® should function without side effects common in other treatments. See more advantages of AAGP®.

Microscope image

Backed by research

Bioavailable icon image

Highly bioavailable

Cellsalive image

Keeps cells alive

Cells icon image

Protects against inflammation

Image of a drawn man

Safe for humans

Cell survival is in our nature

Animals have lived in the arctic since before the last ice-age. To survive in extreme conditions, they rely on inborn anti-freeze glycoproteins (AFGPs) to endure the act of being frozen. AGFPs have been useful in many applications over the years, but they are limited by their cost (approximately $10,000 per gram), instability and size (2,600 to 24,000 Daltons).
Image of a fish
AAGPcells image

Molecules must be less than 1,000 Daltons to pass through cell junctions into neighboring cells and less than 600 Daltons to diffuse through capillaries or cross the blood-brain barrier. AAGP® was invented to be a smaller, more stable synthetic version of AFGPs. They are just 580.96 Daltons and much less expensive to produce.

  • 2002
    Initial public offering
  • 2003
    First intellectual property (IP) filing
  • 2005
    Initial application for pipeline research
  • 2010
    Good Manufacturing Practice processing and toxicology study success
  • 2014
    IP second filing and Type 1 diabetes islet transplantation study
  • 2016
    Preclinical validation in Type 1 diabetes and peer reviewed papers
  • 2016
    IP third filing and induced pluripotent stem cells study for macular degeneration
  • 2019
    Preclinical validation in macular degeneration
  • 2020
    Engage Food and Drug Administration for consultation on Investigational Drugs and Devices approval for topical products
  • 2020
    Large-scale bioproduct validation
  • 2020
    First licensing agreement for topical products
  • 2021
    Published phase one clinical results for Type 1 diabetes
  • 2021
    Orphan disease status approval
  • 2021
    Initiate phase one clinical trial for macular degeneration
  • 2022
    Initiate phase two clinical trial for Type 1 diabetes
  • 2022
    Milestone partnership agreement for biological biosimilar production


  • Molecular formula: C20H35CIF2N4O11
  • Structure: Ala-Ala-Lys-F-C-F-Galactose
  • Molecular mass: M = 580.96 g.mol-1
  • Size: 580.96 Daltons

Solubility (at 25°C)

  • Solubility in water: 650 g.L-1
  • Soluble in water, methanol ethanol and DMSO
  • Lightly lipid soluble

Compound characteristics

  • White powder
  • Highly hygroscopic


  • Stable at a pH of 2 to 14
  • Stable at temperatures of -196°C + 37°C
  • No enzyme degradation from proteases or galactosidases


  • Optimal concentration of 1 to10 mg/ml, depending on cell lines and stress tests
  • Optimal pH of 5.3 to 7.3, depending on cell lines and stress tests
Protokinetix animation image

Mechanism of action

AAGP®’s ability to protect against inflammation-induced cell death in exposure to hydrogen peroxide, UVA and UVC suggests a role for AAGP® in the inflammation pathway. When exposed to an inflammatory mediator, interleukin ß (ILß), the presence of AAGP® reduced COX-2 expression threefold.

Inflammation plays a major role in many pathological conditions suggesting AAGP® may not just be usable in cell and organ storage but also in pharmacological treatments.

Principal investigators

AAGP® has gone through years of international testing by some of the top researchers in the world. Get to know our principal investigators.

Profile image of a man
A global leader in macular research
Profile image of a man

A renowned islet cell transplantation surgeon

Profile image of a man

A pioneering researcher in cellular immunology

Profile image of a man

An esteemed biochemist and toxicologist

AAGP® research

Since 2005, AAGP® has gone through international laboratory testing conducted by some of the top researchers in the world. See their scientific contributions.

Research pipeline

We are moving cell survival forward by addressing the health conditions that affect our lives. See where we are today and where we are heading next.

Invest in AAGP®
AAGP® has the power to change millions of lives – starting with yours.
Image of bar graphs
Image of bar graphs